Filing Flows › Opko Health (OPK) › Q2 2026 › vs Q2 2025
Opko Health (OPK) Q2 2026 vs Q2 2025 (year over year)
Opko Health's revenue rose $6.8M (+4%) from $157M in Q2 2025 to $164M in Q2 2026. The biggest changes: Intellectual Property and Other +$31.1M (+207%); Service −$26.6M (-26%); Product +$2.2M (+5%).
Opko Health, Q2 2026: revenue $164M (+4% year over year), operating margin -4.3%, net loss $8.4M, operating cash flow −$43.5M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Service | $74.5M | $101M | −$26.6M | -26% |
| Intellectual Property and Other | $46.1M | $15.0M | $31.1M | +207% |
| Product | $42.9M | $40.7M | $2.2M | +5% |
| Revenue | $164M | $157M | $6.8M | +4% |
| Income tax benefit | $5.0M | $14.1M | −$9.1M | -65% |
| Net loss | $8.4M | $148M | −$140M | -94% |
| Costs & expenses | $177M | $319M | −$142M | -45% |
| Operating costs | $171M | $217M | −$46.2M | -21% |
| Interest & other, net | $6.4M | $103M | −$96.1M | -94% |
| Cost of revenue | $83.6M | $107M | −$23.8M | -22% |
| Research & development | $33.2M | $30.3M | $2.8M | +9% |
| SG&A | $52.9M | $59.6M | −$6.7M | -11% |
| Other operating costs | $899K | $19.4M | −$18.5M | -95% |
| Operating cash sources | $68.1M | $109M | −$40.5M | -37% |
| Depreciation & amortization | $22.4M | $23.0M | −$618K | -3% |
| Share-based compensation | $2.2M | $2.2M | $0 | 0% |
| Cash used in operations | $43.5M | $83.4M | −$39.9M | -48% |
| Net loss absorbed | $8.4M | $148M | −$140M | -94% |
| Working capital & other | $59.7M | −$39.8M | $99.5M | — |
Questions
How much did Opko Health's revenue grow year over year in Q2 2026?
Opko Health's revenue rose $6.8M (+4%) from $157M in Q2 2025 to $164M in Q2 2026.
What drove Opko Health's revenue change in Q2 2026?
Intellectual Property and Other +$31.1M (+207%); Service −$26.6M (-26%); Product +$2.2M (+5%).